Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole
| Autor: | Anne Mette Dybro, Per Damkier, Maja Hellfritzsch, Torsten Bloch Rasmussen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Simvastatin medicine.medical_specialty Posaconazole Antifungal Agents Statin Itraconazole medicine.drug_class Atorvastatin Anticholesteremic Agents/adverse effects 030106 microbiology Antifungal drug Pharmacology 030226 pharmacology & pharmacy Article Rhabdomyolysis 03 medical and health sciences 0302 clinical medicine Journal Article medicine Humans Drug Interactions cardiovascular diseases Rhabdomyolysis/chemically induced business.industry Anticholesteremic Agents Antifungal Agents/adverse effects nutritional and metabolic diseases General Medicine Middle Aged medicine.disease Surgery Itraconazole/adverse effects Polypharmacy Terbinafine Simvastatin/adverse effects lipids (amino acids peptides and proteins) Female business medicine.drug |
| Zdroj: | Dybro, A M, Damkier, P, Rasmussen, T B & Hellfritzsch, M 2016, ' Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole ', BMJ Case Reports, vol. 2016 . https://doi.org/10.1136/bcr-2016-216457 Dybro, A M, Damkier, P, Rasmussen, T B & Poulsen, M H 2016, ' Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole ', BMJ Case Reports, vol. 2016 . https://doi.org/10.1136/bcr-2016-216457 |
| Popis: | A 47-year-old woman had been treated with high-dose simvastatin for several years. After systemic treatment with the antifungal agent itraconazole, she developed muscle pain and highly elevated levels of creatine kinase and myoglobin. Muscle biopsy was compatible with statin-associated rhabdomyolysis, probably caused by a drug-drug interaction between simvastatin and itraconazole. The patient made full recovery. Three commonly used statins-simvastatin, atorvastatin and lovastatin-are metabolised by the liver enzyme CYP3A4. Several potent inhibitors of this enzyme are known, for example, azole antifungal agents such as itraconazole and posaconazole. If antifungal treatment is indicated in a patient using a CYP3A4-metabolised statin, we recommend (1) topical administration of the antifungal agent if possible, (2) the use of a non-CYP3A4-inhibiting antifungal drug such as terbinafine or (3) temporary discontinuation of statin treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|